DexCom Financials

DXCM Stock  USD 138.70  0.78  0.56%   
Based on the analysis of DexCom's profitability, liquidity, and operating efficiency, DexCom Inc is performing exceptionally good at this time. It has a great probability to report excellent financial results in April. At this time, DexCom's Total Current Assets are very stable compared to the past year. As of the 29th of March 2024, Other Current Liabilities is likely to grow to about 1.3 B, while Other Current Assets are likely to drop about 25.1 M. Key indicators impacting DexCom's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio2.72.8444
Notably Down
Slightly volatile
The financial analysis of DexCom is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for DexCom includes many different criteria found on its balance sheet. For example, investors should never minimize DexCom's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor DexCom's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in DexCom.

Net Income

568.58 Million

With this module, you can analyze DexCom financials for your investing period. You should be able to track the changes in DexCom individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past DexCom Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of DexCom's financial statements are interrelated, with each one affecting the others. For example, an increase in DexCom's assets may result in an increase in income on the income statement.
Evaluating DexCom's financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of DexCom's profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the DexCom's relative financial performance

Chance Of Distress

Less than 9

 
100  
 
Zero
Low
DexCom Inc has less than 9 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for DexCom stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, DexCom's odds of distress score SHOULD NOT be confused with the real chance of DexCom Inc filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as DexCom is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include DexCom's liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in DexCom's official financial statements usually reflect DexCom's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DexCom Inc. For example, before you start analyzing numbers published by DexCom accountants, it's critical to develop an understanding of what DexCom's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of DexCom's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DexCom's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DexCom's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DexCom Inc. Please utilize our Beneish M Score to check the likelihood of DexCom's management manipulating its earnings.

DexCom Company Summary

DexCom competes with Spectral, Medigus, Monogram Orthopaedics, Modular Medical, and Motus GI. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Dexcom operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 6300 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001093557
ISINUS2521311074
CUSIP252131107
RegionNorth America
LocationCalifornia; U.S.A
Business Address6340 Sequence Drive,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.dexcom.com
Phone858 200 0200
CurrencyUSD - US Dollar
You should never invest in DexCom without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of DexCom Stock, because this is throwing your money away. Analyzing the key information contained in DexCom's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

DexCom Key Financial Ratios

Generally speaking, DexCom's financial ratios allow both analysts and investors to convert raw data from DexCom's financial statements into concise, actionable information that can be used to evaluate the performance of DexCom over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that DexCom Inc reports annually and quarterly.

DexCom Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets2.4B4.3B4.9B5.4B6.3B6.6B
Net Debt699.5M1.0B769.2M1.4B2.0B2.1B
Cash446.2M817.6M1.1B642.3M566.3M594.6M
Total Current Assets2.0B3.4B3.7B3.7B4.4B4.6B
Other Current Liab88.5M432.1M125.2M134.3M1.2B1.3B
Retained Earnings(695.7M)(202.1M)(47.4M)479.9M1.0B1.1B
Accounts Payable256.4M163.3M573M901.8M276.4M290.2M
Other Assets14.2M237.8M220.8M369.3M424.7M445.9M
Other Current Assets30M53.9M81.6M192.6M49.3M25.1M
Total Liab1.5B2.5B2.6B3.3B4.2B4.4B
Other Liab5.7M80.9M90M68.7M79.0M83.0M
Long Term Debt1.1B1.7B1.7B1.2B2.4B2.6B
Net Receivables286.3M428.5M514.3M713.3M987.5M1.0B
Inventory119.8M234.7M357.3M306.7M559.6M587.6M
Short Term Debt13.6M16.5M20.5M793.1M21.1M20.0M
Net Tangible Assets864M1.8B2.2B2.1B2.5B2.6B
Good Will18.6M19.3M26.5M25.7M25.2M14.4M
Capital Surpluse1.7B2.1B2.5B2.3B2.6B1.5B

DexCom Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what DexCom's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201920202021202220232024 (projected)
Interest Expense60.3M84.7M102M18.6M20.3M15.5M
Operating Income142.3M299.5M175.4M391.2M597.7M627.6M
Ebit142.3M299.5M175.4M391.2M730.7M767.2M
Research Development273.5M359.9M604.2M484.2M505.8M531.1M
Ebitda164.5M382.7M277.4M416.9M916.7M962.5M
Net Income101.1M493.6M154.7M341.2M541.5M568.6M
Income Tax Expense3.1M(268.6M)19.2M49.6M168.9M177.3M
Income Before Tax104.2M225M173.9M390.8M710.4M745.9M
Total Revenue1.5B1.9B2.4B2.9B3.6B3.8B
Gross Profit931.5M1.3B1.7B1.9B2.3B2.4B
Cost Of Revenue544.5M646.6M768M1.0B1.3B1.4B
Tax Provision3.1M(268.6M)19.2M49.6M168.9M177.3M
Interest Income26.4M16.1M1.7M18M135M141.8M
Net Interest Income(33.9M)(68.6M)(100.3M)(18.6M)114.7M120.4M

DexCom Key Cash Accounts

Cash flow analysis captures how much money flows into and out of DexCom Inc. It measures of how well DexCom is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money DexCom brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money DexCom had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what DexCom has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201920202021202220232024 (projected)
Change In Cash(690.7M)371.8M235.4M(410.3M)(75.8M)(72.0M)
Free Cash Flow134.5M276.6M53.3M304.7M511.9M537.5M
Depreciation48.7M67.1M102M155.9M186M195.3M
Capital Expenditures180M199M389.2M364.8M236.6M248.4M
Net Income101.1M493.6M154.7M341.2M541.5M568.6M
End Period Cash Flow446.4M818.2M1.1B643.3M567.5M291.3M
Other Non Cash Items51.7M93.6M209.3M39.8M(78M)(74.1M)
Change To Inventory(49.1M)(114.5M)(112.2M)49.3M(252.6M)(240.0M)
Investments(835.2M)(807.7M)193.2M(138.5M)(1.1B)(1.1B)
Change Receivables(60M)(142.3M)(75.5M)(199.9M)(179.9M)(170.9M)
Net Borrowings389M836.6M906.2M1.2B1.4B1.4B
Change To Netincome109M(64.3M)242.3M145.9M167.8M84.3M

DexCom Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining DexCom's current stock value. Our valuation model uses many indicators to compare DexCom value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DexCom competition to find correlations between indicators driving DexCom's intrinsic value. More Info.
DexCom Inc is one of the top stocks in shares outstanding category among related companies. It is rated below average in shares owned by insiders category among related companies . The ratio of Shares Outstanding to Shares Owned By Insiders for DexCom Inc is about  917,892,876 . Comparative valuation analysis is a catch-all model that can be used if you cannot value DexCom by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DexCom's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DexCom's earnings, one of the primary drivers of an investment's value.

DexCom Inc Systematic Risk

DexCom's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. DexCom volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on DexCom Inc correlated with the market. If Beta is less than 0 DexCom generally moves in the opposite direction as compared to the market. If DexCom Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one DexCom Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of DexCom is generally in the same direction as the market. If Beta > 1 DexCom moves generally in the same direction as, but more than the movement of the benchmark.

About DexCom Financials

What exactly are DexCom Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include DexCom's income statement, its balance sheet, and the statement of cash flows. Potential DexCom investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although DexCom investors may use each financial statement separately, they are all related. The changes in DexCom's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DexCom's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze DexCom Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as DexCom is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of DexCom has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if DexCom's financials are consistent with your investment objective using the following steps:
  • Review DexCom's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand DexCom's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare DexCom's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if DexCom's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

DexCom Thematic Clasifications

DexCom Inc is part of Medical Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Medical EquipmentView
This theme covers USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in DexCom Stock are looking for potential investment opportunities by analyzing not only static indicators but also various DexCom's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of DexCom growth as a starting point in their analysis.

Price Earnings To Growth Ratio

1.73

At this time, DexCom's Price Earnings To Growth Ratio is very stable compared to the past year.

DexCom March 29, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of DexCom help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of DexCom Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of DexCom Inc based on widely used predictive technical indicators. In general, we focus on analyzing DexCom Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build DexCom's daily price indicators and compare them against related drivers.
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the DexCom Inc information on this page should be used as a complementary analysis to other DexCom's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for DexCom Stock analysis

When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Is DexCom's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.81
Earnings Share
1.29
Revenue Per Share
9.384
Quarterly Revenue Growth
0.269
Return On Assets
0.0641
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.